Garber Alan M 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Apr 17, 2026
Research Summary
AI-generated summary of this filing
Vertex (VRTX) Director Alan Garber Receives Award of 33.898 Units
What Happened
Alan M. Garber, a director of Vertex Pharmaceuticals (VRTX), was granted 33.898 deferred stock units (DSUs) on April 15, 2026. The grant is reported as a derivative award valued at $15,000 (33.898 units × $442.50 per unit). This was an award/grant (transaction code A), not an open‑market purchase or sale.
Key Details
- Transaction date: 2026-04-15; Filing date (Form 4): 2026-04-17 (timely file).
- Grant amount and price: 33.898 deferred stock units at $442.50 per unit; total reported value $15,000.
- Shares owned after transaction: Not specified in the filing.
- Footnote: Each deferred stock unit represents one share and will be paid in common stock upon the earliest of (i) Dr. Garber leaving the board, (ii) a change of control, or (iii) Dr. Garber's disability or death.
- Transaction type: Derivative award (code A) — not an immediate cash transaction or sale.
Context
Deferred stock units are a form of compensation that convert to shares only upon certain triggering events; they do not represent currently tradable shares. This appears to be routine board compensation (modest dollar value) and should be viewed as a grant rather than a market bet. The filing was submitted within the typical Form 4 reporting window.
Insider Transaction Report
- Award
Deferred Stock Units
[F1]2026-04-15$442.50/sh+33.898$15,000→ 33.898 total→ Common Stock (33.898 underlying)
Footnotes (1)
- [F1]Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death.